TNFRSF9 and glioblastoma: Wang et al. [108] demonstrated that CTLX binds to tumor samples from 15 different patients, and co-culture of GBM cell lines with CTLX CAR T cells induces significant GBM cell killing, T-cell activation measured by upregulation of CD69 and 4-1BB, and T-cell degranulation measured by an increase in expression of CD107a.